Trials / Unknown
UnknownNCT05440591
Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes
Effects of Dapagliflozin and Metformin on Vascular Function in Newly-Diagnosed Treatment-Naive Type 2 Diabetes- A Randomised Controlled Trial (DMVascular Study)
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Tan Tock Seng Hospital · Academic / Other
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients.
Detailed description
Trial Design: This is a 12 week randomised controlled open label trial comparing the impact of Dapagliflozin, Metformin and combination therapy on vascular function in newly diagnosed T2DM patients. Trial Participants: Approximately 150 newly diagnosed T2DM patients with randomization 1:1:1 to Metformin XR 500mg twice daily, Dapagliflozin 10 mg daily or Metformin XR 500/Dapagliflozin 5 mg daily Primary Aim : To evaluate the influence of intervention on vascular function. Secondary Aims: 1. To evaluate the influence on other parameters of vascular function and beds. 2. To evaluate the haemodynamics involving blood pressure regulation. 3. To evaluate the effects of SGLT2i versus Metformin on endothelial interactions (vascular permeability) and leukocyte-endothelial interactions (leukocyte rolling, adherence), endothelial regenerative capacity and other endothelial related pathways.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dapagliflozin | Dapagliflozin 10mg tablets |
| DRUG | MetFORMIN 500 Mg Oral Tablet | Metformin 500 mg tablets twice daily |
| DRUG | Dapagliflozin / metFORMIN Pill | Combination pill |
Timeline
- Start date
- 2019-04-01
- Primary completion
- 2023-05-10
- Completion
- 2023-05-10
- First posted
- 2022-07-01
- Last updated
- 2022-07-01
Locations
1 site across 1 country: Singapore
Source: ClinicalTrials.gov record NCT05440591. Inclusion in this directory is not an endorsement.